Correction to:Bone Marrow Transplantation
published online 25 Feb 2019
The original version of this article included some minor typesetting errors in Table 1–a corrected version of which is provided in this correction article and has been corrected in the original article–and one error in text, which has been corrected in the original article. Furthermore, the article was erroneously published with the copyright holders as ‘Springer Nature Limited’, however, since the article is Open Access, the copyright holders should in fact be ‘The Author(s)’. This has also been corrected in the original article.
References
Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92:737–44.
Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2000;111:1122–9.
Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337–43.
Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant. 2004;33:189–95.
Bulley SR, Strahm B, Doyle J, Dupuis LL. Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer. 2007;48:700–4.
Sucak GT, Aki ZS, Yagcí M, Yegin ZA, Ozkurt ZN, Haznedar R. Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience. Transplant Proc. 2007;39:1558–63.
Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010;16:1005–17.
Ruiz Ramos J, Company Albir MJ, Favieres Puigcerver C, Marrero Álvarez P, Megias Vericat JE, Valero García S, et al. CP-129 Defibrotide for sinusoidal obstruction syndrome: a single centre experience. Eur J Hosp Pharm. 2014;21:A52.
Locatelli F, Faraci M, Cesaro S, Pagliara D, Fagioli F, Zecca Marco, et al. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following hematopoietic stem cell transplantation or chemotherapy—results from the Italian Therapeutic Use Protocol. Blood. 2015;126:3107.
Triplett BM, Kuttab HI, Kang G, Leung W. Escalation to high-dose defibrotide in patients with hepatic veno-occlusive disease. Biol Blood Marrow Transplant. 2015;21:2148–53.
Balade Martinez L, Valle LGD, Martin ER, De Sebastian Rueda M, Molia Cabezuelo M, Herrero Ambrosio A. CP-062 Defibrotide for the treatment of severe hepatic veno-occlusive disease. A single centre experience. Eur J Hosp Pharm. 2016;23:A27–A28.
Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the international compassionate-use program. Biol Blood Marrow Transplant. 2016;22:1874–82.
Pol RR, Russell N, Das-Gupta E, Watson L, Rachael L, Byrne J. Incidence and management of hepatic severe veno-occlusive disease in 273 patients in a single centre with defibrotide. Bone Marrow Transplant. 2016;51:1262–4.
Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127:1656–65.
Strouse C, Richardson P, Prentice G, Korman S, Hume R, Nejadnik B, et al. Defibrotide for treatment of severe veno-occlusive disease in pediatrics and adults: an exploratory analysis using data from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2016;22:1306–12.
Yakushijin K, Ikezoe T, Ohwade C, Kudo K, Okamura H, Goto H, et al. Nationwide survey of defibrotide and recombinant human soluble thrombomodulin for treatment of sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51:S77–S78.
Richardson P, Smith A, Triplett B, Kernan N, Grupp S, Antin J, et al. Final efficacy and safety results from a defibrotide expanded-access program for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Bone Marrow Transplant. 2017;52:S64–S65.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Richardson, P., Aggarwal, S., Topaloglu, O. et al. Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). Bone Marrow Transplant 54, 2117–2119 (2019). https://doi.org/10.1038/s41409-019-0507-3
Published:
Issue date:
DOI: https://doi.org/10.1038/s41409-019-0507-3
